MV1035, an ALKBH5 inhibitor, can reduce U87-MG migration and invasiveness via down-regulation of CD73, which is an extrinsic protein involved in the generation of adenosine and overexpressed in glioblastoma [92]. The gene discussed is ALKBH5; the disease is glioblastoma.